Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: you miss a big point

...As a result, now that the ruling from the NDCA is final, there would be no reason for the Company to refrain from releasing a PR based on that ruling itself...

ron, thanks you explained a lot in the past, not that i do understand it completely, but,

what if leckrone has a different view than you, or at least what if leckrone stopps any pr because of playing his game of delay, for various reasons (moore, brown, pds to pay him etc.)

would then, issuing a pr by ptsc, in opposition to leckrone, this potentially mean breach of the comag, or the master agreement?

could this be a reason not to pr the ndca 2nd markman?

Share
New Message
Please login to post a reply